secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mountain Crest Acquisition Corp. V (MCAG)
CIK:        0001859035
Form:       8-K
Filed at:   2022-11-16T23:59:59+00:00
Accession:  0001829126-22-019342
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mountain Crest V to combine with AUM Biosciences at ~$400M valuation; PIPE of $30M sought
--------------------------------------------------------------------------------

- Purchase price of ~$400M; AUM shareholders roll over 100% equity for ~84% of pro forma ownership.
- Targeted PIPE of $30M (not committed) to fund AUM balance sheet and transaction expenses.
- MCAG cash in trust of $69M; assumes 75% redemptions; $17.25M retained.
- AUM is a precision oncology company with pipeline in Phase 2 for AUM001 and AUM601.
- Expected close Q1 2023, subject to customary conditions and approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859035/000182912622019342/0001829126-22-019342-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859035/000182912622019342/mountaincrest5_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-22-019342

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer